#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Mark Kaufmann Email
CFO . Ardelyx
How to contact Mark Kaufmann
Join and see Mark's contact info for free!Current Roles
Employees:
340Revenue:
$24.6MAbout
Ardelyx is focused on enhancing the way people with kidney and cardiovascular diseases are treated by developing innovative first-in-class medicines. Ardelyx's pipeline includes tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, for which the Company is preparing for NDA filing mid-year, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELAￃﾯￆﾒￂﾢ (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin Corporation in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories. For more information, please visit http://www.ardelyx.com/ and connect with us on Twitter @Ardelyx.Ardelyx Address
34175 Ardenwood BoulevardFremont, CA
United States